Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) shares have risen 7.2% since its last earnings report, outperforming the S&P 500; however, consensus estimates have since shifted downward by -48.19%, leading to a Zacks Rank #4 (Sell) and an expectation of below-average returns in the coming months. In comparison, Vertex Pharmaceuticals (VRTX), a peer in the same industry, has gained 3.3% over the past month, with its next quarter earnings expected to increase by +133.1% from the year-ago quarter.

Analysis

Apellis Pharmaceuticals (APLS) has demonstrated notable share price appreciation, rising 7.2% since its last earnings report and outperforming the S&P 500. However, this positive market performance is juxtaposed with a significant deterioration in analyst outlook, as evidenced by a substantial -48.19% downward revision in the consensus estimate over the past month. This negative shift in expectations has contributed to a Zacks Rank #4 (Sell) for APLS, indicating an anticipated below-average return from the stock in the coming months. Furthermore, the company's fundamental metrics appear weak, with subpar VGM Scores of D for Growth, F for Momentum, and D for Value, culminating in an overall aggregate VGM Score of F. In contrast, industry peer Vertex Pharmaceuticals (VRTX) has gained 3.3% over the past month. Vertex reported revenues of $2.77 billion for the quarter ended March 2025, a 3% year-over-year increase, though its EPS of $4.06 was down from $4.76 a year ago. Vertex is expected to post a significant earnings increase of +133.1% year-over-year to $4.24 per share for the current quarter, despite its Zacks Consensus Estimate seeing a minor -1.3% change in the last 30 days, leading to a Zacks Rank #3 (Hold) and a VGM Score of C. The starkly negative sentiment and estimate revisions for APLS suggest its recent stock rally may face headwinds.

Key Decisions for Investors

• Investors should view Apellis Pharmaceuticals' recent 7.2% stock price increase with caution, given the concurrent -48.19% downward revision in consensus estimates and its Zacks Rank #4 (Sell) designation.
• The stock's overall VGM Score of F, reflecting poor grades in growth, value, and momentum, suggests underlying fundamental weaknesses that may not support sustained price appreciation; a pullback could be possible.
• Monitor upcoming earnings releases and any further shifts in analyst estimates closely, as these will be critical in validating or refuting the current negative outlook and determining the sustainability of recent stock performance.